Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.

Authors:
  • CBClifton O Bingham
    Clifton O Bingham
  • CBClifton Bingham
    Clifton Bingham
  • LBLaura Barisoni
    Laura Barisoni
  • ELEileen Lydon
    Eileen Lydon
  • HBH Michael Belmont
    H Michael Belmont

  • 1 April 2005
    • journal article
    • case report
Abstract
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.